$3.81
6.72%
Nasdaq, Tue, Feb 04 2025
ISIN
US0021201035
Symbol
LIFE
Sector
Industry

aTyr Pharma, Inc. Stock price

$3.81
-0.16 4.03% 1M
+1.93 102.66% 6M
+0.19 5.25% YTD
+2.11 124.12% 1Y
-1.82 32.33% 3Y
-1.63 29.96% 5Y
-205.49 98.18% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.24 6.72%
ISIN
US0021201035
Symbol
LIFE
Sector
Industry

Key metrics

Market capitalization $319.82m
Enterprise Value $267.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,113.38
P/S ratio (TTM) P/S ratio 1,332.58
P/B ratio (TTM) P/B ratio 4.42
Revenue growth (TTM) Revenue growth -97.81%
Revenue (TTM) Revenue $240.00k
EBIT (operating result TTM) EBIT $-68.05m
Free Cash Flow (TTM) Free Cash Flow $-67.11m
Cash position $65.99m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 1,326.44
EV/Sales forward 1,108.24
Short interest 0.70%
Show more

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a aTyr Pharma, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
100%

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.24 0.24
98% 98%
100%
- Direct Costs 1.95 1.95
36% 36%
813%
-1.71 -1.71
122% 122%
-713%
- Selling and Administrative Expenses 9.49 9.49
33% 33%
3,954%
- Research and Development Expense 55 55
24% 24%
22,875%
-66 -66
51% 51%
-27,546%
- Depreciation and Amortization 1.95 1.95
36% 36%
813%
EBIT (Operating Income) EBIT -68 -68
45% 45%
-28,355%
Net Profit -64 -64
48% 48%
-26,592%

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Sanjay Shukla
Employees 59
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today